Evaxion is pleased to announce dosing of first patient with EVX-01, Evaxion’s personalized cancer immunotherapy.
Today’s news represents an important milestone for cancer patients and for Evaxion!
As a novel immunotherapy, EVX-01 is designed to engage the immune system to mount a targeted response against neoepitope-expressing solid tumors. Evaxion believes that its state-of-the-art neoepitope detection technology PIONEER in combination with the improved cytokine activation profile observed in preclinical studies of EVX-01 could offer a potential efficacy advantage with reduced toxicities compared to other neoepitope cancer immunotherapies. Moreover, there is a shorter turnaround time (7 weeks) in manufacturing EVX-01 compared to other personalized neoepitope immunotherapies.